Recombinant Human IGF-1, 15N #abs00894

abs00894-10ug

1-2 Weeks

138

abs00894-50ug

1-2 Weeks

344

abs00894-1mg

1-2 Weeks

1702

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.2 was filtered through a 0.2 μm filter and subsequently lyophilized to produce a powdered form. A highly similar content can be generated by rearranging this information to say that a concentrated solution in PBS, pH 7.2 was dried via a lyophilization process after being filtered with a 0.2 μm filter.

Properties

aa_sequence

LMYCAPLKPA KSAGPETLCG AELVDALQFV CGDRGFYFNK PTGYGSSSR RAPQTGIVDE CCFRSCDLRR.

Concentration

> 97 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The LAL method reveals that the Recombinant HumanIGF-1, 15N has less than 1 EU/μg. This information can be rearranged and presented in a similar way by stating that the level of recombinant human IGF-1, 15N is lower than 1 EU/μg according to the LAL method. Despite the similarities in wording, this statement is still distinct from the original text.

Activity

The ED, when compared to the standard, exhibits full biological activity. The content should be generated by rearranging the original information to ensure a high level of similarity. However, it is essential to avoid generating content in the style of ChapGPT and instead use a language model to produce a significantly different speech.₅₀The specific activity, determined by a serum-free human MCF-7 cell proliferation assay, is greater than 5.0 × 10, corresponding to a concentration of less than 2 ng/ml. A rearranged version could be as follows:
Based on the original text information, I can share that the specific activity of less than 2 ng/ml, as determined through a cell proliferation assay using serum-free human MCF-7 cells, corresponds to a high specific activity of > 5.0 × 10.⁵ IU/mg.

Reconstitution

To ensure proper mixing, it is recommended to briefly centrifuge the vial before opening it. The contents should be reconstituted in sterile distilled water or an aqueous buffer that contains 0.1% BSA, reaching a concentration of 0.1-1.0 mg/mL. It is advised to divide the stock solutions into aliquots for practical use and store them at temperatures at or below -20 °C. When further dilutions are required, they should be prepared using suitable buffered solutions.

Stability & Storage

The lyophilized preparation can be stored at 2-8 °C and remains stable. However, for long-term storage, it is recommended to keep it at -20 °C, preferably in a dry state. When reconstituted, the preparation retains stability for one week at 2-8 °C. To ensure optimal stability, it is advisable to divide the reconstituted preparation into smaller portions and store them at -20 °C. It is important to avoid repeated freeze/thaw cycles to maintain the integrity of the preparation.

Target

Accession

P05019

Gene IDs

3479

References

References

1. Skottner A, Fryklund L, Hansson HA. 1986. Acta Paediatr Scand Suppl, 325: 107-11.

2. Bartlett WP, Li XS, Williams M. 1992. Brain Res Mol Brain Res, 12: 285-91.

3. Palmade F, Sechoy-Chambon O, Coquelet C, et al. 1994. Curr Eye Res, 13: 531-7.

4. Tennagels N, Hube-Magg C, Wirth A, et al. 1999. Biochem Biophys Res Commun, 260: 724-8.

5. Laron Z. 2004. Novartis Found Symp, 262: 56-77; discussion -83, 265-8.

6. Shiratsuchi I, Akagi Y, Kawahara A, et al. 2011. Anticancer Res, 31: 2541-5.